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PHOSPHATE MANAGEMENT IN CHRONIC KIDNEY DISEASE: IS IT JUST 
ABOUT THE DAIRY FOODS? 
 
 
The renal dietitian plays a pivotal role in managing high serum phosphate 
levels in chronic kidney disease (CKD). Reducing the phosphate content of 
the diet is essential in treating hyperphosphataemia although this does not 
come without challenges. By successfully managing phosphate as part of a 
team, the outcome should be to reduce mortality through preventing 
incidences of hyperparathyroidism, mineral and bone disorder, vascular 
calcification and cardiovascular events (1, 2).  
 
Chronic Kidney disease 
 
There is limited prevalence data on CKD for the UK. The NHS Kidney Care 
report (2012) states that in England approximately 1.8 million people have 
been diagnosed and are undergoing treatment for CKD. CKD is usually 
asymptomatic so it is of no surprise when the report states that a further 1 
million people may still be undiagnosed(3). Blood pressure management and 
blood tests have been introduced in screening clinics to try and combat this. 
 
The risk of kidney disease rises rapidly with age and almost half of the 
patients commencing dialysis are aged 65 years old and over. Many patients 
requiring dialysis have other co-morbidities such as diabetes and 
cardiovascular disease, which are also major causes of CKD (4)  
 
CKD is defined as either kidney damage or glomerular filtrate rate (GFR) 
<60ml/min/1.73m2 on two consecutive readings for more than 3 months (5). 
The stages are shown in Table 1. 
 
Phosphate 
Phosphate is an essential mineral in the body, mainly found in bones and 
teeth.  Phosphate supports the body to utilise fat, carbohydrates as well as 
synthesising protein. It is essential for the production of adenosine 
triphosphate (ATP) which the body uses to store energy. 30% of phosphate in 
the body is excreted through the intestines and 70% by the kidneys (6). This 
helps the body to maintain a serum phosphate level between 0.8-
1.4mmol/litre. 
 
When the kidneys are healthy parathyroid hormone (PTH), calcitrol; the active 
metabolite of Vitamin D and Fibroblast Growth Factor 23 (FGF23) maintain 
calcium and phosphate homeostasis in the body. When serum calcium levels 
reduce (hypocalcaemia) then PTH is secreted in response, mobilising calcium 
and phosphate from the bone. Calcitrol is activated in the kidney and 
increases intestinal absorption of calcium and phosphate. FGF23 is released 
from the bone in response to elevated serum phosphate levels. FGF23 is 
sensitive to changes in phosphate and is thought to be an early biomarker of 
excess phosphate load, although its response is slow and progressive (7).  
 
PTH increases renal reabsorption of calcium while along with FGF23, reduces 
renal reabsorption of phosphate. Once serum calcium and phosphate levels 
are corrected PTH and FGF23 are suppressed.  
 
As kidney function declines PTH and FGF23 maintain their role to reduce 
renal reabsorption of phosphate. Once GFR is less than 20-25ml/min/1.73m2 
the kidney can no longer excrete phosphate resulting in raised serum 
phosphate levels (8). 
 
 
Dietary requirements 
 
Evidence suggests that the focus of phosphate management is more 
important in the early stages of CKD in order to reduce long term 
complications and delay progression of kidney disease (9, 10). The latest 
guidelines produced by Kidney Disease Improving Global Outcomes (KDIGO) 
(11) recommend prescribing dietary phosphate restriction alone or alongside 
phosphate binders. The guidelines however do acknowledge that the level of 
evidence is weak and high quality RCTs are required to support this. 
 
The renal dietitians role in serum phosphate management is paramount in 
achieving a positive outcome. The role of the renal dietitian is to advise 
patients on phosphate containing foods, suitable alternatives and how to 
match the dose of phosphate binders to the phosphate content of the meal 
(12).  
 
National and international guidelines recommend a daily dietary allowance of 
800mg – 1000mg of phosphate to maintain serum levels of phosphate of 0.9-
1.5 mmol/litre for CKD 3b-5 (not on dialysis) and 1.1-1.7mmol/litre for CKD 5D 
(on dialysis) (11,13,14). 
 
It is also important to consider the fine balance of restricting phosphate intake 
whilst maintaining sufficient dietary calorie and protein intake to prevent 
malnutrition. Shinabergar (2008) showed that low serum phosphate levels and 
low dietary protein intakes in patients with CKD are associated with increased 
mortality and protein energy wasting. It is important to consider the current 
recommendations for protein when reducing phosphate content of the diet;  
 0.75 g/kg IBW/day for patients with stage 4-5 CKD not on dialysis (15) 
 1.0-1.2 g/kg IBW/day for patients treated with dialysis (15,16) 
Table 2 explains IBW. 
 
Dietary management 
Phosphate is present in protein rich foods such as meat, offal, fish, eggs, milk, 
milk products and pulses. Table 3 shows the phosphate content of most 
common foods. 
 
In a healthy individual up to 80% of phosphate is absorbed from foods in the 
intestine (1) which is limited in patients with CKD due to the reduced 
availability of calcitrol. Most patients with CKD are prescribed a vitamin D 
analogue which is usually in the form of 1-alfacalcidol® or zemplar®. This 
medication improves the patients’ ability to absorb up to 60% of phosphate via 
the intestine. Phosphate content of a grain based source has reduced 
bioavailability due to the presence of phytate. This can also affect the uptake 
of calcium and magnesium (10). 
 
As well as considering the natural dietary phosphate from foods, foods that 
have phosphorus-containing additives also need to be accounted for. Table 4 
shows the foods that have phosphorus-containing additives.  
 
Phosphorus-containing additives are especially important in the meat industry 
where they are used as preservatives (18,19,20). They increase water holding 
capacity and meat pH, reduce cooking losses, maintain colour, improve 
protection against microbial growth and improve textural properties (18). The 
EU has prohibited the addition of phosphates in raw meats but allows it in 
cooked meats. It is suggested that the phosphate in the foods containing 
these additives are almost completely absorbed (18,19,21).  Research shows 
that intake from these foods contribute an additional 1000mg/day to a 
patient’s normal intake (18).  
 
High phosphate intakes have been related to a poorer quality diet. Studies 
conducted in the USA related subjects from a low socio-economic group to 
have a higher phosphate intake due to the additives in the foods they 
consumed (1). Indeed with counselling patients were able to lower their 
phosphate level but it was still a challenge due to the lack of information 
provided by the food industry. There is also a lack of awareness in some 
health professionals regarding the addition of phosphates in the form of a 
preservative (21). 
 
The addition of phosphate as a preservative complicates the patients’ ability 
to minimise phosphate intake. The challenge increases due to the lack of 
information on food labels about the total phosphorus content of foods. Even 
food composition tables do not account for the addition of phosphate to foods.  
Studies have related increased serum phosphate as a cardiovascular risk not 
only in patients with CKD but also in patients who have normal renal function 
(20, 22). This supports the need for more public information on the risk of 
excessive phosphate intake and consideration of comprehensive labelling. 
 
Dialysis 
 
Haemodialysis and peritoneal dialysis is limited in its ability to reduce the total 
phosphate as a significant amount is found intracellularly. Phosphate tends to 
be cleared more efficiently in the first half of the treatment compared to the 
second. Therefore diet and phosphate binder medication are the most 
effective way of treating hyperphosphataemia. 
 
 
Phosphate binders 
 
Over the past few years pharmacological treatment in phosphate 
management has expanded and remains a competitive market. Phosphate 
binders are usually introduced when dietary management is limited and the 
serum levels remain above 1.70mmol/litre. Initial binder therapy includes 
calcium based phosphate binders such as calcium carbonate (calcichew®) or 
calcium actetate (phosex®). If the serum phosphate levels remain excessive 
or serum calcium levels increase then an alternative product can be 
considered either solely or as a combination with the calcium based binder. 
Sevelamer carbonate (Renagel®) or lanthanum carbonate (Fosrenol®) are 
examples of non calcium based binders. Companies have produced 
medications that can be swallowed, crushed, chewed, or mixed with food or 
water. While some of these preparations offer patients an alternative to 
tablets, this still does not reduce the drug burden patients have to persevere 
with on a daily basis. 
 
Studies have shown that each phosphate binder has a different binding 
capacity (23). The dietitian will discuss the timing and dose of the phosphate 
binders based on the patients’ meal pattern. Prescribing phosphate binders is 
still an area of development within the profession. 
 
Adherence 
 
The Renal Registry reported that in the UK 56% of haemodialysis patients 
and 69% of peritoneal dialysis patients achieved the audit measures for 
phosphate in 2010 (24). Non- adherence is a common factor in any chronic 
disease. Many patients with CKD have multiple dietary restrictions, a number 
of medications to take and possible multiple co-morbidities to cope with (25). 
 
The Health Foundations “Closing the Gap” through changing relationships 
programme has been introduced to try and enable the patients to take more of 
an active role in their treatment. By sharing the care the aim is to improve the 
experience for both patient and staff. It is important that the patient is fully 
informed about their treatment, including diet and medications, to empower 
and help them with decision making.  
 
A patient centred approach using good communication skills is vital for a 
successful outcome. Knowledge is important but unless the patient is 
engaged and motivated, this alone does not improve a patients’ success. 
Different educational strategies have shown positive outcomes in the short 
term however for the longer term patients need to be able to self manage 
(26). 
 
At Leeds Teaching Hospitals renal unit we have started to recognise our 
patients’ achievements. A patient is nominated by a member of the multi-
disciplinary team. A poster is then developed so that the nominated patients’ 
success can be shared. The aim is to encourage and motivate other patients 
on the unit. Figure 1 illustrates one of the stories of success. Consent was 
gained from the patient for the purpose of reproduction in this article. 
 
 
 
 
 
Summary 
 
The risks of hyperphosphataemia in CKD are well documented. Diet, 
medication and dialysis are recognised as essential factors in the control of 
serum phosphate levels. The challenge in a patient achieving and maintaining 
acceptable serum phosphate levels however, remain. Empowering the patient 
to share the responsibility of their treatment needs to central to achieving 
successful outcomes. 
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Tables for article 
 
 
Table 1 classification of chronic kidney disease (5) 
Stage GFR 
(ml/min/1.73m2) 
Description 
1 >90 Normal or increased GFR, with other evidence of 
kidney damage 
2 60-89 Slight decrease in GFR, with other evidence of 
kidney damage 
3A 45-59 Moderate decrease in GFR, with or without other 
evidence of kidney damage 3B 30-44 
4 15-29 Severe decrease in GFR, with or without other 
evidence of kidney damage 
5  <15 Established renal failure 
5D <15 Receiving renal replacement therapy 
 
 
Table 2 Ideal body weight (15) 
 
Ideal body weight should be calculated from height and ‘ideal’ BMI. ‘Ideal’ would be:  
 20 for those with actual BMI < 20  
 25 for those with BMI > 25  
 actual BMI if it lies between 20-25 
 
 
 
Table 3: phosphate content of commonly consumed foods (6) 
 
Food Phosphate 
content 
mmol/l/100g 
Portion size Phosphate 
content 
(mmol/l) 
Meat 
Lamb/Pork/Beef/Chicken 
Offal 
Pate 
 
7 
11-16 
14.5 
 
100g 
100g 
80g 
 
7 
11-16 
12 
Fish 
Cod/Haddock/Halibut 
Scampi 
Pilchards 
 
7 
10 
9 
 
100g 
170g 
215g 
 
7 
17 
19 
Diary foods and Eggs 
Milk 
Egg 
Double cream 
Condensed Milk 
Hard cheese 
Cream cheese 
Cottage cheese 
 
3 
6.4 
1.7 
8.7 
16 
3.2 
5.2 
 
195g 
50g 
15g 
15g 
30g 
30g 
30g 
 
5 
3.2 
0.25 
1.3 
5 
1 
1.6 
Processed 
cheese/spread 
25 30g 7.5 
Puddings 
Ice cream 
Rice Pudding 
Custard 
Yoghurt 
 
2.9 
2.7 
3.5 
3.1 
 
2 scoops (120g) 
150g 
120g 
125g 
 
3.5 
4 
4.3 
3.4 
Miscellaneous 
Oat based biscuits 
Plain sweet biscuit 
Plain potato crisp 
Tortilla chips 
Peanuts 
Sunflower seeds 
Ready-Brek (milk) 
Porridge (water or milk) 
 
7 
2.8 
3.5 
7.7 
14 
21 
13.5 
1.5 or 4.6 
 
30g 
20g 
40g 
50g 
25g 
16g 
180g 
160g 
 
2.1 
0.6 
1.5 
4 
3.5 
3.3 
24 
2 or 7 
 
 
 
 
Table 4 (17, with permission) 
Phosphate Additive Examples of Foods 
Diphosphates Cakes, instant mashed potatoes and 
cheese 
Triphosphates Fish fingers 
Polyphosphates Dried foods and desserts 
Monostarch Phosphates Ice cream, Pizza, Battered fish, salad 
dressing 
Phosphoric Acid Beer, processed meats e.g. sausages, 
sweets, cakes, chocolates, carbonated 
drinks, jams, vegetable fats and oils 
Calcium phosphate Self-raising flour, cake and pancake 
mixes, powdered milk drinks, instant 
pasta and sauces 
Ammonium Phosphate Baked goods, alcoholic beverages, 
condiments, puddings, baking powder, 
frozen desserts, margarine, whipped 
toppings and yeast foods 
Magnesium Phosphate Salt substitute, prepared mustard 
Dicalcium Diphosphate Cupcake mixes, pie tops, instant pasta 
and sauces, muesli bars, ice cream and 
instant soups 
Phosphate Distarch Phosphate Batters for frozen foods, custards, 
sauces, mayonnaise, salad dressing, 
pies and fillings, instant beverages, dried 
foods, drinking yoghurt, flavoured milk, 
whipped cream, coffee, pre cooked pasta 
and noodles, starch based puddings 
 
